临床试验/IRCT20220211053992N38

IRCT20220211053992N38招募中Unknown

In vivo fasted-state bioequivalence study of Emtricitabine/Tenofovir alafenamide (200/25) tablets manufactured by Shari Pharmaceutical industry compared to innovator product

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年8月26日

适应症

试验速览

阶段: Unknown
状态: 招募中
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 59 years（—）
性别: All

入选标准

•General Health (in terms of Liver, Heart and Kidney)

排除标准

•History of cardiovascular disease, liver and kidney disease
•Alcohol and drug addiction
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Investigating the in vivo bioequivalence of Eplerenone 25 mg

IRCT20210519051345N20Tabriz University of Medical Sciences24

Investigating the in vivo bioequivalence of Eplerenone 50 mg

IRCT20210519051345N45Tabriz University of Medical Sciences24

In vivo Bioequivalence study of Primidone suspensioIn the present study, the products will be administered to healthy volunteers..

IRCT20220211053992N17Tabriz University of Medical Sciences24

Investigating bioequivalence of Omeprazole capsuleIn the present study, the products will be administered to healthy volunteers..

IRCT20220211053992N25Fatak Chemie Pars24

Investigating the in vivo bioequivalence of Escitalopram 20 mg tabletIn the present study, the products will be administered to healthy volunteers.

IRCT20210519051345N55Tabriz University of Medical Sciences24